An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

ABSTRACT

Introduction: A growth in the market for anti-diabetic drugs, along with an ever-increasing population suffering from type 2 diabetes mellitus (T2DM), requires a critical re-evaluation of anti-diabetic drugs used for a long time, in order to provide up-to-date practical prescribing information for clinicians. Alogliptin benzoate was firstly approved in 2010 in Japan for T2DM, both as a monotherapy or in combination with other anti-diabetic drugs.

Areas covered: This article provides a comprehensive review of the latest data on alogliptin benzoate, including hypoglycemic activity and safety.

Expert opinion: The cumulative evidence for alogliptin benzoate is robust with regards to glycemic efficacy and safety. Low hypoglycemia risks and weight changes support its consideration as a first-line medication for T2DM, either as a monotherapy or in combination therapy with other anti-diabetic drugs such as metformin. Ongoing trials will look to better analyze and address its safety and efficacy in pediatric patients and expand our clinical knowledge of this medication.

KEYWORDS:

• DPP-4 inhibitor
• alogliptin benzoate
• type 2 diabetes mellitus
• up-to-date evaluation

Article highlights

• Alogliptin benzoate is an effective and well-tolerated treatment for type 2 diabetes mellitus, monotherapy or in combination with other anti-diabetes drugs.

• Alogliptin benzoate treatment has benefits on blood pressure and nonalcoholic fatty liver progression in patients with type 2 diabetes mellitus.

• Alogliptin benzoate treatment ameliorates the progression of carotid intima-media thickness in patients with type 2 diabetes mellitus.

• The use of alogliptin benzoate is not associated with increased cardiovascular risk.

Declaration of interest

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

The authors are supported by the National Natural Science Foundation of China (81801832), the Postdoctoral Science Foundation of China (2019T120491, 2019M625046), the Medical and Health Science and Technology Project of Zhejiang Province (2019KY6370), the Traditional Chinese Medicine Science and Technology Project of Zhejiang Province (2019ZB117), the Natural Science Foundation of Ningbo (2018A610294) and the K.C. Wong Magna Fund from Ningbo University.